BRPI0919759A2 - polipeptídeos para tratamento e prevenção de adesões - Google Patents

polipeptídeos para tratamento e prevenção de adesões

Info

Publication number
BRPI0919759A2
BRPI0919759A2 BRPI0919759A BRPI0919759A BRPI0919759A2 BR PI0919759 A2 BRPI0919759 A2 BR PI0919759A2 BR PI0919759 A BRPI0919759 A BR PI0919759A BR PI0919759 A BRPI0919759 A BR PI0919759A BR PI0919759 A2 BRPI0919759 A2 BR PI0919759A2
Authority
BR
Brazil
Prior art keywords
polypeptides
prevention
adhesion treatment
adhesion
treatment
Prior art date
Application number
BRPI0919759A
Other languages
English (en)
Inventor
Panitch Alyssa
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of BRPI0919759A2 publication Critical patent/BRPI0919759A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
BRPI0919759A 2008-10-20 2009-10-20 polipeptídeos para tratamento e prevenção de adesões BRPI0919759A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10683408P 2008-10-20 2008-10-20
PCT/US2009/061345 WO2010065206A1 (en) 2008-10-20 2009-10-20 Polypeptide for treating or preventing adhesions

Publications (1)

Publication Number Publication Date
BRPI0919759A2 true BRPI0919759A2 (pt) 2017-03-21

Family

ID=42108870

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919759A BRPI0919759A2 (pt) 2008-10-20 2009-10-20 polipeptídeos para tratamento e prevenção de adesões

Country Status (11)

Country Link
US (1) US9034815B2 (pt)
EP (1) EP2349310B1 (pt)
JP (1) JP5785085B2 (pt)
KR (2) KR101884616B1 (pt)
CN (1) CN102256613B (pt)
AU (1) AU2009322865B2 (pt)
BR (1) BRPI0919759A2 (pt)
CA (1) CA2741302C (pt)
DK (1) DK2349310T3 (pt)
ES (1) ES2507496T3 (pt)
WO (1) WO2010065206A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898230C (en) 2007-01-10 2018-04-24 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
DK2185698T3 (en) 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
WO2010068692A1 (en) * 2008-12-10 2010-06-17 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) * 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CA2832910C (en) 2011-04-12 2019-07-02 Cynthia Lander Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
MX344635B (es) * 2012-03-23 2017-01-04 Amicrobe Inc Composiciones y usos de materiales antimicrobianos con propiedades compatibles con el tejido.
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2016061145A1 (en) * 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
CA2967621A1 (en) * 2014-11-17 2016-05-26 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
AU2016205125A1 (en) * 2015-01-08 2017-07-13 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
JP2018512401A (ja) 2015-03-12 2018-05-17 モイライ マトリックス インコーポレイテッド Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用
KR20200018400A (ko) 2017-04-06 2020-02-19 아미크로베, 인코포레이티드. 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도
RU2741247C1 (ru) * 2020-10-13 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики перитонеальных спаек женского таза

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) * 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) * 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) * 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
FI79651C (fi) * 1982-10-08 1990-02-12 Glaxo Group Ltd Doseringsanordning foer medicin.
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GR861995B (en) * 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP0733059B1 (en) * 1993-12-09 2000-09-13 Thomas Jefferson University Compounds and methods for site-directed mutations in eukaryotic cells
AU2003260668A1 (en) * 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
EP1824336A4 (en) * 2004-12-02 2009-10-14 Univ North Carolina INHIBITION OF PHOSPHORYLATION HSP27 TO TREAT VESICATION DISORDERS
EP1868629B1 (en) * 2005-04-15 2014-10-22 Arizona Biomedical Research Commission Therapeutic fusion peptides for the treatment of metastatic cancer
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
CA2898230C (en) * 2007-01-10 2018-04-24 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
WO2008109794A2 (en) * 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
DK2185698T3 (en) * 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
US20090269406A1 (en) * 2008-04-02 2009-10-29 Alyssa Panitch Therapeutic uses of biocompatible biogel compositions

Also Published As

Publication number Publication date
CN102256613B (zh) 2014-09-10
DK2349310T3 (da) 2014-08-11
CA2741302C (en) 2017-02-28
JP2012506442A (ja) 2012-03-15
KR20170001756A (ko) 2017-01-04
CA2741302A1 (en) 2010-06-10
EP2349310A4 (en) 2012-11-21
WO2010065206A1 (en) 2010-06-10
EP2349310A1 (en) 2011-08-03
US20100098760A1 (en) 2010-04-22
ES2507496T3 (es) 2014-10-15
EP2349310B1 (en) 2014-07-23
JP5785085B2 (ja) 2015-09-24
KR101884616B1 (ko) 2018-08-06
AU2009322865A1 (en) 2010-06-10
US20130101671A9 (en) 2013-04-25
AU2009322865B2 (en) 2013-07-18
CN102256613A (zh) 2011-11-23
KR20110095867A (ko) 2011-08-25
US9034815B2 (en) 2015-05-19

Similar Documents

Publication Publication Date Title
BRPI0919759A2 (pt) polipeptídeos para tratamento e prevenção de adesões
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0917089A2 (pt) métodos e sistemas planos de ação personalizados
BRPI0809978A2 (pt) Dispositivos e métodos de dispensação de gotículas
BRPI0820379A2 (pt) Sistemas e métodos de dispensação de produto médico
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
BRPI0806964A2 (pt) Combinações de agonístico beta-2-adrenoceptor e benzotiazolona
DK2405869T3 (da) Fedmebehandling
HK1183435A1 (en) Frizzled-binding agents and uses thereof
BRPI0910259A2 (pt) métodos de tratamento de inflamação
IL207096A0 (en) Modified leptin polypeptides and their uses
BRPI0908379A2 (pt) sistemas e métodos para obter dentaduras customizadas
BRPI1015379A2 (pt) sistemas de cálculo biométrico e métodos
HK1247197A1 (zh) Psma-結合劑及其用途
BRPI1016199A2 (pt) cobertura de ferimento e kit de tratamento de ferimentos.
BRPI0917288A2 (pt) sensor de biomems e aparelhos e métodos para o mesmo
BR112012004281A2 (pt) uso de metformina tratamento e prevenção de câncer
BRPI0811870A2 (pt) Tratamento e prevenção de influenza
BRPI0816789A2 (pt) Goji e inflamação
BRPI0905715A2 (pt) Composição farmacêutica e kit de componentes
BRPI0816288A2 (pt) Processos e compostos
ZA201100019B (en) Variant hhip1 protein and methods and uses thereof
BRPI0806944A2 (pt) Medicamento para o tratamento de endometriose
DK2154144T3 (da) Oligonukleotider og anvendelse deraf
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL